Clinical & Psychosocial Research

The Jonathan Jaques Children’s Cancer Center (JJCCC) at Miller Children’s is heavily involved in research programs involving blood disorders, cancers, psychosocial issues and long-term survival. JJCCC partners with many local hospitals such as Harbor-UCLA, CHLA, Rady Children’s and national consortiums, such as Children’s Oncology Group (COG), National Association of Children’s Hospitals & Related Institutes (NACHRI) and the Hemophilia & Thrombosis Research Society (HTRS).

Clinical Research

JJCCC is one of the primary institutions that comprise the Children's Oncology Group (COG), an international, cooperative childhood cancer research network that focuses on identifying cancer causes and pioneering new treatments and cures at children’s hospitals. With COG, Miller Children’s enrolls patients on Phase II and III clinical trials. Participation in COG advances research and allows JJCCC to offer the latest and most effective treatments to young patients. JJCCC manages most of the leukemia, brain tumors and bone tumor studies.

JJCCC is also one of only a select group of children’s hospitals designated a Hemophilia Treatment Centers (HTC) and qualifies to participate in the national hemophilia registry, through the Hemophilia & Thrombosis Research Society (HTRS).

• Learn more about JJCCC’s clinical research
• Find a clinical trial

Psychosocial Research

JJCCC is very active in its psychosocial research program. This nationally recognized research program is designed to increase understanding of the needs of young people with cancer, sickle cell disease and other blood disorders. Research results are published and shared with other cancer centers and children’s hospitals locally, nationally and globally to improve medical and supportive care for children, teenagers and families.

• Learn more about JJCCC’s psychosocial research